で公開中です！詳しく見る

Sana Biotechnology

SANA

時価総額 $6.8億

2.27 USD

-0.21

8.47%

終値時点更新済み 10月16日 16:00 EDT

プレマーケット

時間外取引

2.27

0.00

0%

1日

-8.47%

5日間

-18.05%

1か月

-22.26%

3か月

-28.39%

6か月

-34.58%

年初来

-45.82%

1年

-57.25%

5年間

-88.8%

10年間

-93.53%

概要： Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates comprises SC291, SC262, UP421, and others.

従業員数： 142

ヘルスケアバイオテクノロジー

ニュース

ポジティブ

ニュートラル

ネガティブ

センチメント 3か月間

ポジティブ 25%

ニュートラル 75%

ネガティブ 0%

ポジティブ

Sana Biotechnology: A Shot At Diabetes

Sana Biotechnology trades at a steep discount despite promising T1D assets UP421 and SC451. UP421 demonstrated durable insulin production without immunosuppression in early data, positioning SANA as a potential T1D disruptor. Cash runway is limited to 5 quarters at the current burn, making Sana dependent on the near-term success of their pipeline.

Sana Biotechnology: A Shot At Diabetes

ニュートラル

Sana Biotechnology, Inc. (SANA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Sana Biotechnology, Inc. (SANA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Sana Biotechnology, Inc. (SANA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

ニュートラル

Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Sana Biotechnology, Inc. (SANA) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

ニュートラル

Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

ニュートラル

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

ニュートラル

Sana Biotechnology to Present at September 2026 Investor Conferences

SEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at four investor conferences in September. The presentations will feature a business overview and update.

Sana Biotechnology to Present at September 2026 Investor Conferences

ニュートラル

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

ポジティブ

Zacks Investment Research

3 Promising Genomics Stocks to Add to Your Portfolio in 2026

Genomics is reshaping healthcare, and these three stocks - MYGN, SANA and WVE - stand out as rapid advances in personalized medicine and synthetic biology continue to transform the industry.

3 Promising Genomics Stocks to Add to Your Portfolio in 2026

ポジティブ

Zacks Investment Research

Sana (SANA) Upgraded to Buy: Here's What You Should Know

Sana (SANA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Sana (SANA) Upgraded to Buy: Here's What You Should Know

ニュートラル

Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes

Peer-Reviewed Letter to the Editor Describes Updated Long-Term Findings Consistent with Initial Trial Data Featured in NEJM Article Published in 2025

Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes

ニュースランキングを見る

価格チャートは Lightweight Charts™ を使用して実装されています